| 000 | 01845 a2200577 4500 | ||
|---|---|---|---|
| 005 | 20250518080434.0 | ||
| 264 | 0 | _c20201215 | |
| 008 | 202012s 0 0 eng d | ||
| 022 | _a1744-764X | ||
| 024 | 7 |
_a10.1080/14740338.2020.1713090 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWang, Wen | |
| 245 | 0 | 0 |
_aCefoperazone-sulbactam and risk of coagulation disorders or bleeding: a retrospective cohort study. _h[electronic resource] |
| 260 |
_bExpert opinion on drug safety _cMar 2020 |
||
| 300 |
_a339-347 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAnti-Bacterial Agents _xadverse effects |
| 650 | 0 | 4 |
_aBlood Coagulation Disorders _xchemically induced |
| 650 | 0 | 4 |
_aBlood Platelets _xdrug effects |
| 650 | 0 | 4 |
_aCefoperazone _xadverse effects |
| 650 | 0 | 4 |
_aCeftazidime _xadverse effects |
| 650 | 0 | 4 |
_aDrug Therapy, Combination _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHemorrhage _xchemically induced |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aProthrombin Time _xstatistics & numerical data |
| 650 | 0 | 4 |
_aSulbactam _xadverse effects |
| 650 | 0 | 4 |
_aTazobactam _xadverse effects |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aLiu, Yanmei | |
| 700 | 1 | _aYu, Chuan | |
| 700 | 1 | _aTan, Jing | |
| 700 | 1 | _aXiong, Weiyi | |
| 700 | 1 | _aDong, Duo | |
| 700 | 1 | _aLi, Sheyu | |
| 700 | 1 | _aZhang, Rui | |
| 700 | 1 | _aLi, Jijie | |
| 700 | 1 | _aWu, Yu | |
| 700 | 1 | _aZong, Zhiyong | |
| 700 | 1 | _aSu, Na | |
| 700 | 1 | _aZou, Kang | |
| 700 | 1 | _aWu, Guizhi | |
| 700 | 1 | _aSun, Xin | |
| 773 | 0 |
_tExpert opinion on drug safety _gvol. 19 _gno. 3 _gp. 339-347 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/14740338.2020.1713090 _zAvailable from publisher's website |
| 999 |
_c30496042 _d30496042 |
||